Tag Archives: Bexsero®

Novartis: FDA granted accelerated approval of Bexsero® for active immunization to prevent invasive meningococcal disease caused by meningitis B

With today’s approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero’s two-dose regimen offers a flexible dosing schedule, with the first and second doses administered at least … Read the full press release

Vaccination: Novartis to provide meningococcal serogroup B (MenB) vaccine Bexsero® to University of California Santa Barbara

FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada Novartis is pursuing a US license that would allow immediate public health response to … Read the full press release

Novartis vaccination program with MenB vaccine Bexsero® began at Princeton University following campus outbreak

Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials Bexsero, already licensed in Europe, Australia and Canada, is the only broad coverage vaccine to help protect against MenB disease MenB is … Read the full press release